NRx Pharmaceuticals Future Growth
Future criteria checks 5/6
NRx Pharmaceuticals is forecast to grow earnings and revenue by 59.7% and 55.4% per annum respectively while EPS is expected to grow by 60.7% per annum.
Key information
59.7%
Earnings growth rate
60.74%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 55.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Aug 2026 |
Recent future growth updates
Recent updates
NRXP: Expanded Access And Defense-Focused Neuroplastic Program Will Drive Future Upside
Analysts have lifted their price target for NRx Pharmaceuticals stock from $25 to $45, citing updated assumptions that include a higher projected profit margin of 16.73%, a future P/E of 11.54, a discount rate of 7.24% and an implied revenue growth outlook that has been revised to 720.14%. What's in the News for NRx Pharmaceuticals NRx Pharmaceuticals formed NRx Defense Systems, a Florida based research and development subsidiary focused on neuroplastic treatments that combine D cycloserine with robotic enabled Transcranial Magnetic Stimulation.
NRXP: Psychedelics Policy Shift And FDA Progress Will Drive Upside Potential
Analysts have adjusted their price target on NRx Pharmaceuticals from $36.75 to $42.00, citing updated assumptions on discount rates, revenue growth expectations, profit margins, and future P/E. These changes reflect recent research highlighting potential benefits from the White House shift on psychedelics policy.Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 992 | 163 | 122 | 150 | 1 |
| 12/31/2027 | 157 | 6 | 36 | 33 | 4 |
| 12/31/2026 | 14 | -30 | -13 | -13 | 4 |
| 6/30/2026 | 3 | -23 | -21 | -20 | N/A |
| 3/31/2026 | 2 | -25 | -15 | -15 | N/A |
| 12/31/2025 | 1 | -29 | -14 | -14 | N/A |
| 9/30/2025 | 0 | -38 | -12 | -12 | N/A |
| 6/30/2025 | N/A | -34 | -12 | -12 | N/A |
| 3/31/2025 | N/A | -24 | -10 | -10 | N/A |
| 12/31/2024 | N/A | -25 | -11 | -11 | N/A |
| 9/30/2024 | N/A | -20 | -12 | -12 | N/A |
| 6/30/2024 | N/A | -25 | -14 | -14 | N/A |
| 3/31/2024 | N/A | -26 | -19 | -19 | N/A |
| 12/31/2023 | N/A | -30 | -22 | -22 | N/A |
| 9/30/2023 | N/A | -36 | -27 | -27 | N/A |
| 6/30/2023 | N/A | -39 | -28 | -28 | N/A |
| 3/31/2023 | N/A | -37 | -35 | -35 | N/A |
| 12/31/2022 | N/A | -40 | -40 | -40 | N/A |
| 9/30/2022 | N/A | -60 | -43 | -43 | N/A |
| 6/30/2022 | N/A | -88 | -48 | -48 | N/A |
| 3/31/2022 | N/A | -81 | -45 | -45 | N/A |
| 12/31/2021 | N/A | -93 | -38 | -38 | N/A |
| 9/30/2021 | N/A | -108 | -27 | -27 | N/A |
| 6/30/2021 | N/A | -76 | -16 | -16 | N/A |
| 3/31/2021 | N/A | -76 | -4 | -4 | N/A |
| 12/31/2020 | N/A | -52 | -2 | -2 | N/A |
| 9/30/2020 | N/A | -8 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NRXP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).
Earnings vs Market: NRXP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NRXP is expected to become profitable in the next 3 years.
Revenue vs Market: NRXP's revenue (55.4% per year) is forecast to grow faster than the US market (12.9% per year).
High Growth Revenue: NRXP's revenue (55.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NRXP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 21:32 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NRx Pharmaceuticals, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Thomas Shrader | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |